Zaprutko Tomasz, Florczak-Wyspiańska Jolanta, Kopciuch Dorota, Paczkowska Anna, Ratajczak Piotr, Dorszewska Jolanta, Nowakowska Elżbieta, Kus Krzysztof
Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, 7 Rokietnicka St, 60-806 Poznan, Poland.
Department of Neurology, Poznan University of Medical Sciences, 49 Przybyszewskiego St, 60-355 Poznan, Poland.
Healthcare (Basel). 2021 Aug 5;9(8):999. doi: 10.3390/healthcare9080999.
Stroke is a major cause of morbidity in industrialized countries, representing 8% of total deaths across Europe in 2017. It is also a very costly disorder, frequently caused by atrial fibrillation. We aimed to calculate the cost of stroke hospitalization in 2018 in Poznań (Poland). We also intended to present patients with the first AF diagnosis at the time of stroke. The study was conducted from January 2019 to July 2020. Data were obtained from hospital records and from the hospital accounting department. Out of 164 patients included in the study, 41 had AF and in 18 cases AF was first diagnosed at the time of stroke. The cost of hospitalization in Poznań was EUR 139,257.21 (x¯= EUR 849.13). Among those with concomitant AF, the general cost of inpatient care was EUR 33,859.18 (x¯= EUR 825.83). Considering those who had AF first diagnosed during hospitalization the cost was EUR 16,248.97 (x¯= EUR 906.24). Stroke is associated with high costs of inpatient care, which turned out to be higher among those with AF first diagnosed at the time of stroke. The number of patients who used oral anticoagulants at the time of admission was relatively low. The most frequently used NOAC was dabigatran.
中风是工业化国家发病的主要原因,在2017年占欧洲总死亡人数的8%。它也是一种成本高昂的疾病,常由心房颤动引起。我们旨在计算2018年波兰波兹南中风住院治疗的费用。我们还打算介绍在中风时首次诊断为房颤的患者。该研究于2019年1月至2020年7月进行。数据来自医院记录和医院会计部门。在纳入研究的164名患者中,41名患有房颤,18例在中风时首次诊断出房颤。波兹南的住院费用为139,257.21欧元(平均值=849.13欧元)。在伴有房颤的患者中,住院护理总费用为33,859.18欧元(平均值=825.83欧元)。对于那些在住院期间首次诊断出房颤的患者,费用为16,248.97欧元(平均值=906.24欧元)。中风与住院护理的高成本相关,事实证明,在中风时首次诊断出房颤的患者中成本更高。入院时使用口服抗凝剂的患者数量相对较少。最常用的非维生素K拮抗剂是达比加群。